Metabolic & weight · Peptide
Cagrilintide
Also known as with semaglutide = CagriSema
A long-acting amylin mimic that enhances fullness, often paired with semaglutide.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Activates amylin receptors that slow gastric emptying and signal satiety, complementing GLP-1.
Benefits & effects studied
- Added weight loss when combined with semaglutide
- Improved appetite control
Research state
Phase III (CagriSema) ongoing; not yet approved as standalone.
Dosing & pharmacokinetics
Weekly subcutaneous (trial protocols). Half-life: ~7 days.
Dosing information is educational only. Cagrilintide decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described 2010s by Novo Nordisk Origin: Developed by Novo Nordisk (as AM833/NNC0174-0833) as a long-acting amylin analog for obesity, built on a pramlintide-like backbone; entered Phase I in the 2010s and is studied alone and combined with semaglutide as CagriSema..
Molecular structure
An acylated 37-amino-acid amylin analog with key amino-acid substitutions and a C20 fatty-diacid chain for once-weekly dosing.
Frequently asked questions
Is Cagrilintide FDA-approved?
Investigational — Phase 3 trials (not approved) On Jevity's evidence scale, Cagrilintide is graded "In human trials". Reclassification for compounding is not the same as FDA approval.
What is Cagrilintide used for?
A long-acting amylin mimic that enhances fullness, often paired with semaglutide. Activates amylin receptors that slow gastric emptying and signal satiety, complementing GLP-1. Studied effects include: Added weight loss when combined with semaglutide; Improved appetite control. This is educational information, not a recommendation to use it.
Is Cagrilintide legal in the UAE?
UAE / DHA status: Not available — investigational
Is Cagrilintide banned in sport?
WADA status: Not prohibited
What is Cagrilintide's Jevity Score?
Cagrilintide has a Jevity Score of 58/100 — a proprietary composite of evidence strength (7/10), regulatory clarity (5/10) and supply verifiability (4/10). It reflects how established and legitimate the compound is, not a recommendation.
Related metabolic & weight peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.